Cordis: FDA approves stent system for carotid artery disease

By Lisa Kerner

Charlotte, N.C., Sept. 26 - The Food and Drug Administration granted Cordis Endovascular marketing approval for its Precise Nitinol Stent and Angioguard Emboli Capture Guidewire to treat carotid artery disease, or clogged neck arteries.

The Cordis carotid system has been studied in over 3,000 patients in the landmark Sapphire study and found to be less invasive compared to carotid endarterectomy.

"No other carotid artery stent and embolic protection system has been studied as extensively in as wide a range of high-risk patients as Precise and Angioguard," Cordis Corp. vice president, worldwide clinical and regulatory affairs, Dennis Donohoe said in a news release.

Based in Miami, Cordis is an endovascular research company and a division of Johnson & Johnson.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.